Where can I buy Organovo shares?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Organovo's stock price today?
How much is an ONVO stock worth?
One share of ONVO stock can currently be purchased for approximately $3.90. How much money does Organovo make? Organovo has a market capitalization of $33.95 million and generates $2.20 million in revenue each year. The medical research company earns $-16.83 million in net income (profit) each year or ($1.36) on an earnings per share basis.
What is the PE (price targets) ratio of Organovo?
Only 26.29% of the stock of Organovo is held by institutions. The P/E ratio of Organovo is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
When is Organovo's next earnings release?
View Organovo's Short Interest. When is Organovo's next earnings date? Organovo is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022. View our earnings forecast for Organovo.
How has Organovo's stock price performed in 2022?
Organovo's stock was trading at $3.63 on January 1st, 2022. Since then, ONVO shares have decreased by 42.4% and is now trading at $2.09. View the...
When is Organovo's next earnings date?
Organovo is scheduled to release its next quarterly earnings announcement on Tuesday, June 21st 2022. View our earnings forecast for Organovo .
How were Organovo's earnings last quarter?
Organovo Holdings, Inc. (NASDAQ:ONVO) released its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($1.00)...
When did Organovo's stock split? How did Organovo's stock split work?
Shares of Organovo reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. T...
Who are Organovo's key executives?
Organovo's management team includes the following people: Mr. Keith E. Murphy , Exec. Chairman & Principal Exec. Officer (Age 50, Pay $397.18k)...
What is Taylor Crouch's approval rating as Organovo's CEO?
3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com . Taylor Crouch has an approval rating of 38% among Organovo's employees. This...
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include Orchard Therapeutics (ORTX) , Brookline Capital Acquisition (BCAC) , SAB Biotherapeutics (SA...
What other stocks do shareholders of Organovo own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutic...
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
What is Organovo Holdings?
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded in April 2007 and is headquartered in Solana Beach, CA.
What is the symbol for Organovo?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
What is the P/E ratio of Organovo?
The P/E ratio of Organovo is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
When will Organovo reverse split?
Shares of Organovo reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.
Does Organovo pay dividends?
Organovo does not currently pay a dividend.
Organovo Holdings Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Organovo target price is determined by taking all analyst projections and averaging them out.
Organovo Holdings Target Price Projection
Organovo Holdings' current and average target prices are 2.68 and 0.00, respectively. The current price of Organovo Holdings is the price at which Organovo Holdings is currently trading. On the other hand, Organovo Holdings' target price is what analysts think the stock is worth or could sell for in the future.
Organovo Holdings Analyst Ratings
Organovo Holdings' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Organovo Holdings stock, and they use a lot of effort and time to analyze it and arrive at a rating.
About Organovo Holdings Target Price Projections
Organovo Holdings's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Organovo Holdings and even bonds.
Additional Organovo Holdings Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens.
Additional Organovo Holdings Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens.
Currently Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios.
What is Organovo 2021?
Wainwright Global Life Sciences Conference. The conference is being held on March 9-10, 2021 virtually. Keith Murphy, Executive Chairman of Organovo, will provide an overview of the Company's business during the presentation. A webcast of Organovo’s presentation will be accessible through the Investors & Media section of the company’s website at www.organovo.com. A replay of the webcast will be available on Organovo’s website for 90 days following the conference. About Organovo Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company’s proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo’s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas. Forward Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on February 8, 2021. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. Investor Contact Amato and Partners, LLCInvestor Relations [email protected]
When is Organovo meeting 2021?
(Nasdaq: ONVO), today announced that the Company’s annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of a majority of the shares entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by proxy at this meeting. Approximately 45.6%
When is the next stockholder meeting?
On August 6, 2020, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) for its 2020 Annual Meeting of Stockholders to be held virtually on Tuesday, September 15, 2020 at 9:00 a.m. (Pacific Daylight Time).
What is forward-looking statement?
Forward-looking statements include, but are not limited to, statements regarding the Company’s ability to satisfy the continued listing requirements of The Nasdaq Capital Market. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties.
Stock Price Forecast
The 1 analysts offering 12-month price forecasts for Organovo Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate of 30.00. The median estimate represents a +960.07% increase from the last price of 2.83.
Analyst Recommendations
The current consensus among 1 polled investment analysts is to Hold stock in Organovo Holdings Inc. This rating has held steady since August, when it was downgraded from a Buy rating. Move your mouse over past months for detail
How many articles has The Fool written on Organovo?
The Fool has written over 200 articles on Organovo Holdings.
What is governance score?
The governance score is comprised of weighted key performance indicators related to leadership, management, and business model.
What is the environmental score?
The environmental score is comprised of weighted key performance indicators related to natural capital, innovation, and climate change.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ONVO Broker Recommendations Summary
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ONVO as an investment opportunity.
